文献速递眼底病与葡萄膜炎

阿柏西普生物类似药MYL-1701P与参照阿柏西普治疗糖尿病黄斑水肿:INSIGHT随机临床试验

Aflibercept Biosimilar MYL-1701P vs Reference Aflibercept in Diabetic Macular Edema: The INSIGHT Randomized Clinical Trial.
PubMed 文献 · JAMA Ophthalmol · 2024-01-01

该双盲随机临床试验在美国、欧洲、日本和印度77个中心比较了阿柏西普生物类似药MYL-1701P与参照阿柏西普(Eylea)治疗糖尿病黄斑水肿的疗效与安全性。共355例参与者随机分组,第8周最佳矫正视力字母评分变化分别为6.60和6.56个字母,调整后平均差异0.04个字母(90%CI -1.16至1.24),达到等效界值。结论认为MYL-1701P在疗效上临床等效,安全性和免疫原性相当,支持其作为参照阿柏西普的替代选择。

要点

  • 第8周BCVA字母评分变化:MYL-1701P组6.60个字母 vs 参照阿柏西普组6.56个字母,调整后差异0.04个字母(90%CI -1.16至1.24),达到等效。
  • 第8周中心子区域厚度变化:MYL-1701P组-112 μm vs 参照阿柏西普组-124 μm,调整后差异12 μm(90%CI -3至26 μm)。
  • 治疗中出现的不良事件发生率两组相近,治疗诱导或增强的抗药抗体发生率MYL-1701P组2.8% vs 参照阿柏西普组5.7%。

核心结论

  • MYL-1701P在疗效方面显示临床等效,安全性和免疫原性与参照阿柏西普相当,这些发现支持将MYL-1701P作为参照阿柏西普的替代选择。

研究设计与样本

  • 双盲随机临床试验,纳入美国、欧洲、日本和印度77个中心的18岁及以上1型或2型糖尿病伴中心性糖尿病黄斑水肿患者,研究眼BCVA字母评分73至38(ETDRS视力表)。
  • 共355例参与者随机分配至MYL-1701P组(179例,50.4%)或参照阿柏西普组(176例,49.6%),平均(SD)年龄62.2(9.2)岁,男性216例(60.8%)。
  • 干预为MYL-1701P(0.5 mg瓶装)或参照阿柏西普每4周连续5次玻璃体腔注射,之后每8周至第52周。
  • 主要终点为第8周BCVA字母评分较基线变化的最小二乘均值(SE)的调整后差异,等效界值为-3至+3个字母。

主要发现

  • 第8周BCVA平均(SE)变化:MYL-1701P组6.60(0.55)个字母 vs 参照阿柏西普组6.56(0.55)个字母,调整后平均差异0.04个字母(90%CI -1.16至1.24),达到主要终点。
  • 第8周CST平均(SE)变化:MYL-1701P组-112(7)μm vs 参照阿柏西普组-124(7)μm,调整后平均差异12 μm(90%CI -3至26 μm)。
  • 治疗中出现的不良事件:眼部MYL-1701P组30.9%(55/178) vs 参照阿柏西普组29.5%(52/176);严重眼部0.6%(1/178) vs 1.1%(2/176);非眼部65.2%(116/178) vs 65.3%(115/176);严重非眼部16.9%(30/178) vs 11.9%(21/176)。
  • 52周内平均(SD)总注射次数:MYL-1701P组8.4(2.1)次 vs 参照阿柏西普组8.7(1.8)次。
  • 治疗诱导或治疗增强的抗药抗体发生率:MYL-1701P组2.8%(5/177) vs 参照阿柏西普组5.7%(10/176)。

关键数值与推荐

  • 主要终点等效界值为-3至+3个字母,第8周BCVA调整后平均差异0.04个字母(90%CI -1.16至1.24),达到等效。
  • 第8周CST调整后平均差异12 μm(90%CI -3至26 μm)。

临床怎么用

  • 原文结论认为这些发现支持将MYL-1701P作为参照阿柏西普的替代选择。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Biosimilars may be lower-cost alternatives to originator biologic products, potentially offering expanded access or reduced economic burden, but have not been evaluated with aflibercept in diabetic macular edema (DME). OBJECTIVE: To compare efficacy and safety of MYL-1701P, an aflibercept biosimilar, with reference aflibercept (Eylea [Regeneron]) in DME. DESIGN, SETTING, AND PARTICIPANTS: This was a double-masked, randomized clinical trial that included participants at 77 centers across the US, Europe, Japan, and India. Included in the analysis were individuals 18 years and older with type 1 or type 2 diabetes with central DME and best-corrected visual acuity (BCVA) letter score of 73 to 38 in the study eye using an Early Treatment Diabetic Retinopathy Study (ETDRS) chart. Study data were analyzed from October to December 2021. INTERVENTIONS: Formulations of MYL-1701P (0.5-mg vial) or reference aflibercept every 4 weeks for 5 consecutive intravitreal injections, followed by every 8 weeks through week 52. MAIN OUTCOMES AND MEASURES: The primary outcome was the adjusted difference in least squares mean (SE) change from baseline BCVA letter score at week 8 with an equivalence margin of -3 to +3 letters. Secondary outcomes included change in central subfield thickness (CST), BCVA, number of injections over 52 weeks, incidence of adverse events (AEs), and antidrug antibodies (ADAs). RESULTS: A total of 355 participants (mean [SD] age, 62.2 [9.2] years; 216 male [60.8%]) were randomized to MYL-1701P (179 participants [50.4%]) and aflibercept (176 participants [49.6%]). At week 8, mean (SE) change in BCVA was 6.60 (0.55) letters vs 6.56 (0.55) letters in the MYL-1701P vs aflibercept groups. The adjusted mean difference of 0.04 letters (90% CI, -1.16 to 1.24 letters) met the primary outcome. At week 8, mean (SE) change in CST was -112 (7) μm vs -124 (7) μm in the MYL-1701P vs aflibercept groups (adjusted mean difference, 12 μm; 90% CI, -3 to 26 μm). The incidence of treatment-emergent AEs in the MYL-1701P and aflibercept arms were ocular (30.9% [55 of 178] vs 29.5% [52 of 176]), serious ocular (0.6% [1 of 178] vs 1.1% [2 of 176]), nonocular (65.2% [116 of 178] vs 65.3% [115 of 176]), and serious nonocular (16.9% [30 of 178] vs 11.9% [21 of 176]). The mean (SD) total number of injections was 8.4 (2.1) vs 8.7 (1.8) in the MYL-1701P vs aflibercept groups. The incidence of treatment-induced or treatment-boosted ADAs was 2.8% (5 of 177) vs 5.7% (10 of 176) in the MYL-1701P vs aflibercept arms. CONCLUSIONS AND RELEVANCE: MYL-1701P demonstrated clinical equivalence in regard to efficacy, with comparable safety and immunogenicity, to reference aflibercept. These findings support use of MLY-1701P as an alternative to reference aflibercept. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03610646.

来源:JAMA Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Bressler SB, Barve A, Ganapathi PC, et al. Aflibercept Biosimilar MYL-1701P vs Reference Aflibercept in Diabetic Macular Edema: The INSIGHT Randomized Clinical Trial. JAMA Ophthalmol. 2024. PMID: 39264599. doi:10.1001/jamaophthalmol.2024.3458

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。